DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients
Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].
Authors
- Marc E. Key
- François Cherifi (ORCID: https://orcid.org/0000-0003-3842-7168)
- Stéphanie Lheureux (ORCID: https://orcid.org/0000-0003-4405-5890)
- Germana Tognon (ORCID: https://orcid.org/0000-0003-3935-4992)
- Alison J. Davis (ORCID: https://orcid.org/0000-0003-4425-7871)
- Florence Joly (ORCID: https://orcid.org/0000-0001-6168-4942)
- Emma Hudson (ORCID: https://orcid.org/0000-0002-0505-5049)
- David S.P. Tan (ORCID: https://orcid.org/0000-0001-9087-5262)
- Chel Hun Choi (ORCID: https://orcid.org/0000-0002-0199-6669)
- Domenica Lorusso (ORCID: https://orcid.org/0000-0003-0981-0598)
- I. L. Ray-Coquard
- María Jesús Rubio (ORCID: https://orcid.org/0000-0003-3682-3597)
- Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1903-7001)
- Xavier Paolettí (ORCID: https://orcid.org/0000-0002-1250-0040)
- Jérôme Alexandre
- Jean Emmanuel Kurtz
Institutions
- Université Claude Bernard Lyon 1 (FR)
- National University of Singapore (SG)
- Université Paris Cité (FR)
- Canberra Hospital (AU)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre François Baclesse (LU)
- National University Cancer Institute, Singapore (SG)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hospital Universitario Reina Sofía (ES)
- Saitama International Medical Center (JP)
- National University Hospital (SG)
- Humanitas (United States) (US)
- Velindre Cancer Centre (GB)
- University of the Sacred Heart (JP)
- Hôpital Civil, Strasbourg (FR)
- Institut Curie (FR)
- Sungkyunkwan University (KR)
- Saitama Medical University (JP)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1080/14796694.2025.2496133
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00